Trial Profile

A Multicenter, Non-Randomized, Phase II Study of Regorafenib for Advanced Urothelial Cancer Following Prior Chemotherapy

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 07 Aug 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Regorafenib (Primary)
Indications Bladder cancer; Carcinoma; Urogenital cancer
Focus Therapeutic Use

Most Recent Events

02 Apr 2020 Planned End Date changed from 1 Dec 2019 to 1 Apr 2020.
15 Feb 2020 Status changed from recruiting to discontinued due to slow accrual as per results presented at the 2020 Genitourinary Cancers Symposium
15 Feb 2020 Results (n=17) presented at the 2020 Genitourinary Cancers Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com